Titration of human brain type-B monoamine oxidase
Tóm tắt
The interaction of the substrate-selective irreversible inhibitor J-508 [N-methyl-N-propargyl-(1-indanyl)-ammonium hydrochloride] with the B form of human brain monoamine oxidase has been investigated, and the conditions necessary for this inhibitor to “titrate” the concentration of this enzyme form determined. It was found that the concentration of monoamine oxidase-B determined in this way was the same when either benzylamine or β-phenethylamine was used to assay for activity, which would indicate that this enzyme form is not heterogeneous. Furthermore, the variation in activity from sample to sample was found to be due to a variation in the concentration of available monoamine oxidase-B active centers, rather than due to a variation in the molecular turnover numbers of this enzyme form towards its amine substrates.
Tài liệu tham khảo
Fowler, C. J., Callingham, B. A., Mantle, T. J., andTipton, K. F. 1978. Monoamine oxidase A and B: A useful concept? Biochem. Pharmacol. 27:97–101.
Johnston, J. P. 1968. Some observations on a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17:1285–1297.
Knoll, J., andMagyar, K. 1972. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5:393–408.
Tipton, K. F., Houslay, M. D., andGarrett, N. J. 1973. Allotopic properties of human brain monoamine oxidase. Nature (London), New Biol. 246:213–214.
Roth, J. A. 1976. Evidence for a single catalytic binding site on human brain type B monoamine oxidase. J. Neurochem. 27:1107–1112.
Rando, R. R. 1974. Chemistry and enzymology of somek cat inhibitors. Science 185:320–324.
Abeles, R. H., andMaycock, A. L. 1976. Suicide enzyme inactivators. Acc. Chem. Res. 9:313–319.
Fowler, C. J., andCallingham, B. A. 1978. The inhibition by clorgyline of 5-hydroxytryptamine deamination in the rat liver. J. Pharm. Pharmacol. 30:304–309.
Fowler, C. J., andCallingham, B. A. 1979. The inhibition of rat heart type A monoamine oxidase by clorgyline as a method for the estimation of enzyme active centers. Mol. Pharmacol. 16:546–555.
Oreland, L., andFowler, C. J. 1979. The activity of human brain and thrombocyte monoamine oxidase in relation to various psychiatric disorders. II. The nature of the changed activity. Pages 389–396,in Singer, T. P., Von Korff, R. W., andMurphy, D. L. (eds.), Monoamine Oxidase: Structure, Function and Altered Functions, Academic Press, New York (in press).
Egashira, T., Ekstedt, B., Kinemuchi, H., Wiberg, Å., andOreland, L. 1976. Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat. Med. Biol. 54:272–277.
Fowler, C. J., andOreland, L. 1979. Substrate-selective interaction between monoamine oxidase and oxygen. Pages 145–151,in Singer, T. P., Von Korff, R. W., andMurphy, D. L. (eds.), Monoamine Oxidase: Structure, Function and Altered Functions, Academic Press, New York.
Nelson, D. L., Herbet, A., Pétillot, Y., Pichat, L., Glowinski, J. andHamon, M. 1979. [3H]Harmaline as a specific ligand of MAO A. I. Properties of the active site of MAO A from rat and bovine brains. J. Neurochem. 32:1817–1827.
Murphy, D. L. 1976. Clinical, genetic, hormonal and drug influences on the activity of human platelet monoamine oxidase. Pages 341–351,in Wolstenholme, G. E. W., andKnight, J. (eds.), Monoamine Oxidase and Its Inhibition. Ciba Foundation Symposium 39, Elsevier, Exerpta Medica, North Holland, Amsterdam.
Oreland, L. 1979. The activity of human brain and thrombocyte monoamine oxidase in relation to various psychiatric disorders. I. MAO activity in some disease states. Pages 379–387,in Singer, T. P., Von Korff, R. W., andMurphy, D. L. (eds.), Monoamine Oxidase: Structure, Function and Altered Functions, Academic Press, New York.
Squires, R. F. 1968. Additional evidence for the existence of several forms of mitochondrial monoamine oxidase in the mouse. Biochem. Pharmacol. 17:1401–1409.
Lyles, G. A., andGreenawalt, J. W. 1978. Possible heterogeneity of type B monoamine oxidase in pig heart mitochondria. Biochem. Pharmacol. 27:923–935.
Knoll, J., Ecsery, Z., Magyar, K., andSatory, E. 1978). Novel (−)-deprenyl-derived selective inhibitors of B-type monoamine oxidase. Biochem. Pharmacol. 27:1739–1747.
Tam, C. F., Kopple, J. D., Wang, M., andSwenseid, M. D. 1975. Alterations of monoamine oxidase activity in uremia. Kidney Int. 7:S-328–S-332.
Buffoni, F., Ignesti, G., Prisino, R., andCortesini, C. 1977. Platelet monoamine oxidase, plasma benzylamine oxidase and liver mixed function oxidase in cirrhotic patients. Med. Biol. 55:109–111.
Callingham, B. A., andLaverty, R. 1973. Studies on the nature of the increasing monoamine oxidase activity in the rat heart after adrenalectomy. J. Pharm. Pharmacol. 25:940–947.
Fowler, C. J., Ekstedt, B., Egashira, T., Kinemuchi, H., andOreland, L. 1979. The interaction between human platelet monoamine oxidase, its monoamine substrates and oxygen. Biochem. Pharmacol. 28:3063–3068.
Markwell, M. A. K., Haas, S. M., Bieber, L. L., andTolbert, N. E. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:206–210.
Houslay, M. D., andTipton, K. F. 1973. The reaction pathway of membrane-bound rat liver mitochondrial monoamine oxidase. Biochem. J. 135:735–750.
Fowler, C. J., andCallingham, B. A. 1978. Substrate-selective activation of rat liver mitochondrial monoamine oxidase by oxygen. Biochem. Pharmacol. 27:1995–2000.
Roth, J. A. 1979). Effect of drugs on inhibition of oxidised and reduced forms of MAO. Pages 153–168,in Singer, T. P., Von Korff, R. W., andMurphy, D. L. (eds.), Monoamine Oxidase: Structure, Function and Altered Functions, Academic Press, New York.
Youdim, M. B. H., andHolzbauer, M. 1976. Physiological aspects of the oxidative deamination of monoamines. Pages 105–124,in Wolstenholme, G. E. W., andKnight, J. (eds.), Monoamine Oxidase and Its Inhibition, Ciba Foundation Symposium 39, Elsevier, Exerpta Medica/North-Holland, Amsterdam.